期刊文献+

混合型高脂血症治疗新见识 被引量:1

New Insights in Treatment of Combined Hyperlipidemia
下载PDF
导出
摘要 他汀类药物有降低甘 油三酯(TG)作用,也可用于治疗混合型高脂血症:单用他汀类或贝特类降脂疗效欠佳时可联合用药。他汀类与贝特类合用治疗混合型高脂血症,可提高疗效一般安全;但仍亡掌握适应证;需注意与某些药物的相互作用;加强监测,尤其在治疗初期。 Statins can also reduce the trigl -yceride, and be used in treatment of combined hyperlipidemia. When the statin or fibrate using alone, its lowering lipids effect is not satisfied the combination of both drugs is rational and necessary. The combined therapy of statins and fibrates can increase the iowering lipid effects. and usually ts safety. But controlling the indication; paying attention in drug interaction; augmenting the observation and monitoring the adverse reaction of drugs are still necessary.
作者 游凯
出处 《当代医学》 2001年第6期18-21,共4页 Contemporary Medicine
关键词 混合型高脂血症 降脂药 治疗 适应证 药物联用 combined hyperlipidemia, lipid lowering agents, treatment, indication, combined therapy
  • 相关文献

参考文献10

  • 1.Familial Combined Hyperlipidemia[].Manual of Lipid Disorders.1999
  • 2Stein EA.Statins and triglyceride reduction[].Preven Cardiol.1998
  • 3Athyros VG,Papageorgiou AA,Hatzikonstandinou HA et al.Safety and etficacy of long-term statin-fibrate combination in patients with refratory familia combined hyperlipidemia[].The American Journal of Cardiology.1997
  • 4Jordine A,Holdaas H.Fluvastatin in combination with cyclosporin in renal transplrant recipients a review of clinical and safety experience[].Journal of Clinical Pharmacy and Therapeutics.1997
  • 5Davignon J,Hanefeld M,Nakaya N,et al.Clinical efficacy and safety of cerivastatin: summary of pivotal phase ⅡB/Ⅲ studies[].The American Journal of Cardiology.1998
  • 6Shepherd J.Fibrates and statins in the treatment of hyperlipi-daemia: an appraisal of their efficacy and safety[].European Heart Journal.1995
  • 7Zambon,D,Ros,E,Rodriguez-Villar,C.Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidema: additive effects of combination treatment on lipid regulation[].Metabolism.1999
  • 8Transon C,Leemann T,Dayer P.In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450isozymes(CYP2C9,CYP2D6and CYP3A4)by HMG-CoA reductase inhibitors[].European Journal of Clinical Pharmacology.1996
  • 9RG Bakker-Arkema,MH Davidson,RJ Goldstein,RJ Davignon,SL Isaacsohn,SR Weiss,LM Keilson,WV Brown,VT Miller,LJ Shurzinske.Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[].The Journal of The American Medical Association.1996
  • 10Stein E A,Lane M,Laskarzewski P.Comparison of statins in hypertriglyceridemia[].The American Journal of Cardiology.1998

同被引文献15

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部